Image source: © 2025 Krish Capital Pty.Ltd 

Highlights

  • Oxford Nanopore reported H1-2025 revenue of ~GBP105.6m and reiterated full-year guidance; CEO succession announced
  • Oxford Biomedica’s interim report showed H1 revenue ~GBP73.2m and a revenue backlog of c.GBP222m at 30 June 2025
  • PureTech plc held roughly $320m of cash/equivalents at 30 June 2025, giving runway into 2028 at the PLC level per the company’s disclosures

The UK biotech and life-sciences sector presents a diverse mix of therapeutics developers, diagnostics innovators, and service/platform businesses listed across the FTSE Main Market and AIM. This snapshot highlights ten companies with recent H1 or interim updates, showcasing revenue trends, cash positions, order books, and upcoming clinical or regulatory milestones. The selection spans both established players and smaller-cap names, illustrating the breadth of scientific innovation and commercial activity in the UK market while also reflecting the specific execution, funding, and sector risks each company faces.

As of 24 September 2025, Oxford Nanopore Technologies (LSE:ONT) reported H1-2025 revenue of GBP105.6 million, up 28% year-over-year on a constant currency basis. The company reiterated full-year guidance and announced that CEO Gordon Sanghera plans to step down by the end of 2026. Key areas to watch include higher-throughput PromethION uptake and clinical pilot roll-outs.

PureTech Health (LSE:PRTC) held approximately US$320 million in cash at the PLC level as of 30 June 2025, providing a financial runway into 2028. The company continues to advance late-stage programmes and launch new founded entities, with near-term readouts from these programmes representing potential catalysts.

Oxford Biomedica (LSE:OXB) reported H1-2025 revenue of GBP73.2 million, up 44% year-over-year, with a revenue backlog of approximately GBP222 million at 30 June 2025. The company is focusing on converting its backlog into revenue and improving margins as new capacity comes online.

Genus plc (LSE:GNS) announced preliminary FY-25 results showing group revenue growth and improved profitability. Key operational drivers include execution of the China joint venture and rollout of gene-edited traits, while risks include regulatory developments and commodity cyclicality.

Allergy Therapeutics (LSE:AGY) reported an unaudited cash balance of GBP12.8 million for the year ended 30 June 2025. Regulatory milestones include a German MAA decision for Grass MATA MPL and a Phase I/IIa peanut VLP readout expected later in 2025. Funding flexibility and execution of commercial plans remain key areas to monitor.

hVIVO (LSE:HVO) recorded H1-2025 revenue of GBP24.2 million, with a weighted contracted order book of approximately GBP40 million at 30 June 2025 and cash of GBP23.3 million. The company is monitoring conversion of its pipeline into signed work and margin recovery following M&A integrations.

Oxford BioDynamics (LSE:OBD) reported that its EpiSwitch® CiRT test influenced treatment decisions in 61% of cases in a 205-patient cohort, while its PSE test continues to be used in clinical pathways, including private NHS care. Key items to watch include reimbursement, guideline inclusion, and early-stage commercial adoption.

ANGLE plc (LSE:AGL) posted H1-2025 revenue of GBP0.8 million with a net loss of GBP9.3 million. The company is focusing on scaling commercial revenue, converting collaborations into recurring services, and expanding clinical use cases.

EKF Diagnostics (LSE:EKF) reported H1-2025 revenue of GBP25.2 million, with gross margin improving to approximately 50% and adjusted EBITDA up year-over-year. Contract wins, consumables growth, and execution on placements are key factors for the second half of the year.

Polarean Imaging (LSE:POLX) has expanded clinical installations in the US and NHS centres and submitted a Phase III protocol to the FDA in August 2025. The company is monitoring adoption, clinical workflow integration, and reimbursement expansion, while managing capital equipment sales cycles and cash requirements.